[Seite 94↓]


4S 1994: Scandinavian Simvastatin Survival Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994, 344, S. 1383-1398.

Bellosta 1998: S. Bellosta, F. Bernini, N. Ferri et al.: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 1998, 137, S. 101-109.

Blanco-Colio 2002: L. M. Blanco-Colio, A. Villa, M. Ortega et al.: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002, 161, S. 17-26.

Chamley-Campbell 1979: J. Chamley-Campbell, G. R. Campell, R. Ross: The Smooth Muscle Cell in Culture. The American Physiological Society. 1979, 59 (1), S. 1-61.

Corti 2002: R. Corti, V. Fuster, Z. A. Fayad et al.: Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions. Circulation. 2002, 106, S. 2884-2887.

Coux 1996: O. Coux, K. Tanaka, A. L. Goldberg: Structure and Function of the 20S and 26S Proteasomes. Annu. Rev. Biochem. 1996, 65, S. 801-849.

Craiu 1997: A. Craiu, M. Gaczynska, T. Akopian et al.: Lactacystin and clasto-Lactacystin β -Lactone Modify Multiple Proteasome β -Subunits and Inhibit Intracellular Protein Degradation and Major Histocompatibility Complex Class I Antigen Presentation. J. Biol. Chem. 1997, 272, S. 13437-13445.

DeMartino 1999: G. N. DeMartino, C. A. Slaughter: The Proteasome, a Novel Protease Regulated by Multiple Mechanisms. J. Biol. Chem. 1999, 274, S. 22123-22126.

Desterro 2000: J. M. P. Desterro, M. S. Rodriguez, R. T. Hay: Regulation of transcription factors by protein degradation. Cell. Mol. Life Sci. 2000, 57, S. 1207-1219.

[Seite 95↓]

Dichtl 2003: W. Dichtl, M. J. Frick, H. F. Alber et al.: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thrombi. Vacs. Biol. 2003, 23, S. 58-63.

Dick 1996: L. R. Dick, A. A. Cruickshank, L. Grenier et al.: Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin. J. Biol. Chem. 1996, 271, S. 7273-7276.

Drexler 2000: H. C. Drexler, W. Risau, M. A. Konerding: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 2000, 14, S. 65-77.

Endres 1998: M. Endres, U. Laufs, Z. Huang et al.: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 1998, 95, S. 8880-8885.

Fenteany 1995: G. Fenteany, R. F. Standaert, W. S. Lane et al.: Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonin Modification by Lactacystin. Science. 1995, 268, S. 726-730.

Fenton II 2002: J.W. Fenton, II, W. P. Jeske, J. L. Catalfamo et al.: Statin Drugs and Dietary Isoprenoids Downregulate Protein Prenylation in Signal Transduction and Are Antithrombotic and Prothrombolytic Agents. Biochemistry (Moscow). 2002, 67, S. 85-91.

Ferrell 2000: K. Ferrell, C. R. M. Wilkinson, W. Dubiel, C. Gordon: Regulatory subunit interactions of the 26S proteasome, a complex problem. TIBS. 2000, 25, S. 83-88.

Forth 199 6: C. Keller, G. Wolfram, N. Zöllner: Fettstoffwechsel; Lipidsenker: Pharmakotherapie bei Fettstoffwechselstörungen. Hrsg.: W. Forth, D. Henschler, W. Rummel, K. Starke: Allgemeine und Spezielle Pharmakologie und Toxikologie. 7., Heidelberg, Spektrum Akademischer Verlag, 1997, S. 553-561.

Gao 2000: Y. Gao, S. Lecker, M. J. Post et al.: Inhibition of ubiquitin-proteasome pathway-mediated I κ B α degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 2000, 106, S. 439-448.

Goldstein 1990: J. L. Goldstein, M. S. Brown: Regulation of the mevalonat pathway. Nature. 1990, 343, S. 425-430.

[Seite 96↓]

Groll 1997: M. Groll, L. Ditzel, J. Löwe et al.: Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997, 386, S. 463-471.

Groll 2000: M. Groll, M. Bajorek, A. Köhler et al.: A gated channel into the proteasome core particle. Nature structural biology. 2000, 7 (11), S. 1062-1067.

Guijarro 1998: C. Guijarro, L. M. Blanco-Colio et al.: 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture. Circulation Research. 1998, 83, S. 490-500.

Hall 1998: A. Hall: Rho GTPases and the Actin Cytoskeleton. Science. 1998, 279, S. 509-514.

Harrison 1997: D. G. Harrison: Cellular and Molecular Mechanism of Endothelial Cell Dysfunction. J. Clin. Invest. 1997, 100, S. 2153-2157.

Heinemeyer 1997: W. Heinemeyer, M. Fischer et al.: The Active Site of the Eukaryotic 20 S Proteasome and Their Involvement in Subunit Precursor Processing. J. Biol. Chem. 1997, 272 (40), S. 25200-25209.

Hernandez-Perera 2000: O. Hernandez-Perera, D. Perez-Sala, E. Soria, S. Lamas: Involvement of Rho GTPases in the Transcriptional Inhibition of Preproendothelin-1 Gene Expression by Simvastatin in Vascular Endothelial Cells. Circulation Research. 2000, 87, S. 616-622.

Hernandez-Presa 2002: M. A. Hernandez-Presa, J. L. Martin-Ventura, M. Ortego et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002, 160, S. 49-58.

Istvan 2001: E. S. Istvan, J. Deisenhöfer: Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. Science. 2001, 292, S. 1160-1164.

Istvan 2003: E. Istvan: Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis Supplements. 2003, 4, S. 3-8.

Kisselev 1999: A. F. Kisselev, T. N. Akopian et al.: The Size of Peptide Generated from Protein by Mammalian 26 and 20 S Proteasomes. J. Biol. Chem. 1999, 274 (6), S. 3363-3371.

[Seite 97↓]

Kisselev 2000: A. F. Kisselev, Z. Songyang, A. L. Goldberg: Why does Threonin, and Not Serin, Function as the Active Site Nucleophile in Proteasomes?. J. Biol. Chem. 2000, 275 (20), S. 14831-14837.

Kisselev 2001: A. F. Kisselev, A. L. Goldberg: Proteasome inhibitors: from research tools to drug candidates. Chemistry & Biology. 2001, 8, S. 739-758.

Koh 2000: K. K. Koh: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovascular Research. 2000, 47, S. 648-657.

Kumar 2002: B. Kumar, C. Andreatta et al.: Mevastatin Induces Degeneration and Decreases Viability of cAMP-Induced Differentiated Neuroblastoma Cells in Culture by Inhibiting Proteasome Activity, and Mevalonic Acid Lactone Prevents These Effects. Journal of Neuroscience Research. 2002, 68, S. 627-635.

Laufs 2000: U. Laufs, J. K. Liao: Direct Vascular Effects of HMG-CoA Reductase Inhibitors. Trends of Cardiovascular Medicine. 2000, 10, S. 143-148.

Laufs und Liao 2000: U. Laufs, J. K. Liao: Targeting Rho in Cardiovascular Diseases. Circulation Research. 2000, 87, S. 526-528.

Laufs, Endres 2000: U. Laufs, M. Endres, N. Stagliano et al.: Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 2000, 106, S. 15-24.

Laufs, Liao 1998: U. Laufs, J. K. Liao: Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase. J. Biol. Chem. 1998, 273 (37), S. 24266-24271.

Laufs, Marra 1999: U. Laufs, D. Marra et al.: 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27 Kip1. J. Biol. Chem. 1999, 274 (31), S. 21926-21931.

Lee 1998: D. H. Lee, A. L. Goldberg: Proteasome inhibitors: valuable new tools for cell biologists. Cell Biology. 1998, 8, S. 397-403.

Lottspeich 1998: F. Lottspeich, H. Zorbas: Bioanalytik. 1., Heidelberg - Berlin, Spektrum Akademischer Verlag GmbH, 1998, S. 40-41.

[Seite 98↓]

Löwe 1995: J. Löwe, D. Stock et al.: Crystal Structure of the 20S Proteasome from Archaeon T. acidophilium at 3.4 A Resolution. Science. 1995, 268, S. 533-539.

MAAS 1994: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study. Lancet. 1994, 344, S. 633-638.

Meiners 2002: S. Meiners, M. Laule, W. Rother et al.: Ubiquitin-Proteasome Pathway as a New Target for the Prevention of Restenosis. Circulation. 2002, 105, S. 483-489.

Meske 200 3: V. Meske, F. Albert, D. Richter, J. Schwarze, T. G. Ohm: Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. European Journal of Neuroscience. 2003, 17 (1), S. 93-102.

MIRACLE 2001: Dr. med. Gregory G. Schwartz et al.: Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. JAMA. 2001, 285 (13), S. 1711-1718.

MRFIT 1982: Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial. JAMA. 1982, 248 (12), S. 1465-1477.

Murray 2002: S. S. Murray, K. N. Tu, K. L. Young, E. J. Bochmann Murray: The Effects of Lovastatin on Proteasome Activities in Highly Purified Rabbit 20 S Proteasome Preparations and Mouse MC3T3-E1 Osteoblastic Cells. Metabolism. 2002, 51 (9), S. 1153-1160.

Negre-Aminou 1997: P. Negre-Aminou, A. K. van Vliet et al.: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochimica et Biophysica Acta. 1997, 1345 (3), S. 259-268.

Ortego 1999: M. Ortego, C. Bustos, M. A. Hernandez-Presa et al.: Atorvastatin reduces NF- κ B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999, 147, S. 253-261.

Pye 200 3: J. Pye, F. Ardeshirpour, A. McCain et al.: Proteasome inhibition ablates activation of NF- κ B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol. 2003, 284 (3), S. 919-926.

[Seite 99↓]

Rao 1999: S. Rao, D. C. Porter, X. Chen et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethylglutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA. 1999, 96, S. 7797-7802.

RECIFE 1999: J. Dupuis, J.-C. Tardif, P. Cernacek, P. Theroux: Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes (The RECIFE Trial). Circulation. 1999, 99, S. 3227-3233.

Rock 1994: K. L. Rock, C. Gramm, L. Rothstein et al: Inhibitors of the Proteasome Block the Degradation of Most Cell Proteins and the Generation of Peptides Presented on MHC Class I Molecules. Cell. 1994, 78, S. 761-771.

Serajuddin 1991: A. T. M. Serajuddin, S. A. Ranadive, E. M. Mahoney: Relative lipophilicities, solubilities, and structure pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 1991, 80, S. 830-834.

Stobbe 1996: Stobbe, Baumann: Innere Medizin. 7. überarbeitete und erweiterte Auflage, Berlin / Wiesbaden, Ullstein Mosby GmbH & Co, 1996, S. 321.

Takemoto 2001: M. Takemoto, J. K. Liao: Pleiotropic Effects of HMG-CoA Reductase Inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21(11), S. 1712-1719.

van Vliet 1995: A. K. van Vliet, C. F. van Thiel et al.: Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochimica et Biophysica Acta. 1995, 1245, S. 105-111.

Werner 2002: N. Werner, G. Nickenig, U. Laufs: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol. 2002, 97, S. 105-116.

Wojcik 2000: C. Wojcik, M. Bury, T. Stoklosa et al.: Lovastatin and simvastatin are modulators of the proteasome. The International Journal of Biochemistry & Cell Biology. 2000, 32, S. 957-965.

WOSCOPS 1998: West of Scotland Coronary Prevention Study Group: Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study. Circulation. 1998, 97, S. 1440-1445.

[Seite 100↓]

Yeh 2002: E. T. H. Yeh: Ubiquitin, Proteasome, and Restenosis A Brave New World for cardiovascular Research. Circulation. 2002, 105, S. 408-410.

Zelvyte 2002: I. Zelvyte, R. Domainatiene, M. Crisby, S. Janciauskiene: Modulation of inflammatory mediators and PPAR γ and NF κ B expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacological Research. 2002, 45 (2), S. 147-154.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: